- Home
- MHN vs ESPR Comparison
MHN vs ESPR Comparison
Compare MHN & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MHN | ESPR |
|---|---|---|
| Founded | 1997 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.6M | 898.5M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | MHN | ESPR |
|---|---|---|
| Price | $10.28 | $4.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.67 |
| AVG Volume (30 Days) | 59.2K | ★ 6.5M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $303,802,000.00 |
| Revenue This Year | N/A | $25.45 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $8.69 | $0.69 |
| 52 Week High | $10.81 | $4.13 |
Technical Indicators
Market Signals| Indicator | MHN | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 60.61 |
| Support Level | $10.25 | $3.63 |
| Resistance Level | $10.34 | $4.13 |
| Average True Range (ATR) | 0.09 | 0.21 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 14.55 | 60.19 |
Price Performance
Historical ComparisonAbout MHN Blackrock MuniHoldings New York Quality Fund Inc.
BLACKROCK MUNIHOLDINGS NEW YORK QUALITY FUND, INC. is a closed-ended management investment company. The fund's investment objective is to provide shareholders with current income exempt from federal income tax and New York State and New York City personal income taxes.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.